The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

N/ACompletedNCT01195805

Regional Hospital Holstebro25 enrolled

Overview

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

Purpose of the study is to examine the effect of amiloride and spironolactone on 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsewave velocity, augmentation index central bloodpressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory bloodpressure

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Essential Hypertension

Interventions

SpironolactoneDRUG

1 tablet twice a day for 28 days

PlaceboOTHER

1 tablet twice a day for 28 days

AmilorideDRUG

1 tablet twice a day for 28 days

Eligibility

Sex: ALLMin age: 40 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hypertension, * BMI 18,5-30, * non-smoker Exclusion Criteria: * Smoking * Not using contraceptives * Other illnesses * Drug or alcohol abuse

Locations (1)

Departments of medical research and medicine

Holstebro, Denmark

Outcomes

Primary Outcomes

Bloodpressure

Time frame: 24-hours and examination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.